Mochida Pharmaceutical Co., Ltd. (4534.T)
JPY 3090.0
(0.16%)
JPY 3090.0
(0.16%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 369 Million JPY | 94.21% |
| 2022 | 190 Million JPY | 0.0% |
| 2021 | - JPY | 0.0% |
| 2020 | - JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| 2018 | - JPY | -100.0% |
| 2017 | 46 Million JPY | -50.0% |
| 2016 | 92 Million JPY | -81.6% |
| 2015 | 500 Million JPY | 0.0% |
| 2014 | 500 Million JPY | -42.86% |
| 2013 | 875 Million JPY | 0.0% |
| 2012 | 875 Million JPY | 0.0% |
| 2011 | 875 Million JPY | -56.25% |
| 2010 | 2 Billion JPY | 300.0% |
| 2009 | 500 Million JPY | -54.55% |
| 2008 | 1.1 Billion JPY | -35.29% |
| 2007 | 1.7 Billion JPY | -45.16% |
| 2006 | 3.1 Billion JPY | -20.51% |
| 2005 | 3.9 Billion JPY | -54.12% |
| 2004 | 8.5 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - JPY | 0.0% |
| 2024 Q1 | - JPY | -100.0% |
| 2023 Q2 | 676 Million JPY | -0.73% |
| 2023 Q3 | 681 Million JPY | 0.74% |
| 2023 Q1 | 681 Million JPY | 0.0% |
| 2023 FY | 369 Million JPY | 94.21% |
| 2023 Q4 | 369 Million JPY | -45.81% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2022 Q4 | - JPY | 0.0% |
| 2022 FY | 190 Million JPY | 0.0% |
| 2022 Q1 | - JPY | 0.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | - JPY | 0.0% |
| 2021 FY | - JPY | 0.0% |
| 2021 Q1 | - JPY | 0.0% |
| 2020 Q4 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 FY | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q1 | - JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | - JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q1 | - JPY | 0.0% |
| 2019 Q4 | - JPY | 0.0% |
| 2018 FY | - JPY | -100.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 Q1 | - JPY | 0.0% |
| 2018 Q4 | - JPY | 0.0% |
| 2017 FY | 46 Million JPY | -50.0% |
| 2017 Q4 | - JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2017 Q1 | - JPY | 0.0% |
| 2016 Q2 | 500 Million JPY | 0.0% |
| 2016 Q3 | 500 Million JPY | 0.0% |
| 2016 Q1 | 500 Million JPY | 0.0% |
| 2016 Q4 | - JPY | -100.0% |
| 2016 FY | 92 Million JPY | -81.6% |
| 2015 Q2 | 500 Million JPY | 0.0% |
| 2015 FY | 500 Million JPY | 0.0% |
| 2015 Q4 | 500 Million JPY | 0.0% |
| 2015 Q3 | 500 Million JPY | 0.0% |
| 2015 Q1 | 500 Million JPY | 0.0% |
| 2014 Q3 | 687 Million JPY | 0.0% |
| 2014 Q2 | 687 Million JPY | -21.49% |
| 2014 FY | 500 Million JPY | -42.86% |
| 2014 Q1 | 875 Million JPY | 0.0% |
| 2014 Q4 | 500 Million JPY | -27.22% |
| 2013 Q2 | 875 Million JPY | 0.0% |
| 2013 Q4 | 875 Million JPY | 0.0% |
| 2013 FY | 875 Million JPY | 0.0% |
| 2013 Q1 | 875 Million JPY | 0.0% |
| 2013 Q3 | 875 Million JPY | 0.0% |
| 2012 FY | 875 Million JPY | 0.0% |
| 2012 Q2 | 875 Million JPY | 0.0% |
| 2012 Q3 | 875 Million JPY | 0.0% |
| 2012 Q4 | 875 Million JPY | 0.0% |
| 2012 Q1 | 875 Million JPY | 0.0% |
| 2011 FY | 875 Million JPY | -56.25% |
| 2011 Q3 | 3.37 Billion JPY | -42.55% |
| 2011 Q2 | 5.87 Billion JPY | 0.0% |
| 2011 Q4 | 875 Million JPY | -74.07% |
| 2011 Q1 | 5.87 Billion JPY | 193.75% |
| 2010 Q2 | 1.99 Billion JPY | 299.8% |
| 2010 Q1 | 500 Million JPY | 0.0% |
| 2010 Q3 | 1.99 Billion JPY | 0.0% |
| 2010 FY | 2 Billion JPY | 300.0% |
| 2010 Q4 | 2 Billion JPY | 0.05% |
| 2009 Q3 | 800 Million JPY | 0.0% |
| 2009 Q4 | 500 Million JPY | -37.5% |
| 2009 FY | 500 Million JPY | -54.55% |
| 2009 Q2 | 800 Million JPY | 0.0% |
| 2008 Q4 | 1.1 Billion JPY | 0.0% |
| 2008 FY | 1.1 Billion JPY | -35.29% |
| 2007 FY | 1.7 Billion JPY | -45.16% |
| 2006 FY | 3.1 Billion JPY | -20.51% |
| 2005 FY | 3.9 Billion JPY | -54.12% |
| 2004 FY | 8.5 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 16.89 Billion JPY | 97.815% |
| Takeda Pharmaceutical Company Limited | 4843.75 Billion JPY | 99.992% |
| Sumitomo Pharma Co., Ltd. | 418.88 Billion JPY | 99.912% |
| Shionogi & Co., Ltd. | 11.62 Billion JPY | 96.824% |
| Wakamoto Pharmaceutical Co.,Ltd. | 100.52 Million JPY | -267.058% |
| Nippon Shinyaku Co., Ltd. | 2.87 Billion JPY | 87.152% |
| Kaken Pharmaceutical Co., Ltd. | 3.85 Billion JPY | 90.416% |
| Eisai Co., Ltd. | 206.74 Billion JPY | 99.822% |
| Morishita Jintan Co., Ltd. | 425 Million JPY | 13.176% |
| Hisamitsu Pharmaceutical Co., Inc. | 2.1 Billion JPY | 82.429% |
| Fuso Pharmaceutical Industries,Ltd. | 12.72 Billion JPY | 97.1% |
| Nippon Chemiphar Co., Ltd. | 16.98 Billion JPY | 97.827% |
| Tsumura & Co. | 79.69 Billion JPY | 99.537% |
| Kissei Pharmaceutical Co., Ltd. | 1.72 Billion JPY | 78.633% |
| Torii Pharmaceutical Co., Ltd. | 244 Million JPY | -51.23% |
| Towa Pharmaceutical Co., Ltd. | 202.35 Billion JPY | 99.818% |
| Fuji Pharma Co., Ltd. | 28.94 Billion JPY | 98.725% |
| Zeria Pharmaceutical Co., Ltd. | 47.58 Billion JPY | 99.225% |
| KYORIN Holdings, Inc. | 20.94 Billion JPY | 98.238% |
| Taiko Pharmaceutical Co.,Ltd. | 3.8 Billion JPY | 90.312% |
| Daito Pharmaceutical Co.,Ltd. | 8.71 Billion JPY | 95.768% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 60 Million JPY | -515.0% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | 10.545% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.48 Billion JPY | 96.11% |
| Sawai Group Holdings Co., Ltd. | 82.89 Billion JPY | 99.555% |
| Cyfuse Biomedical K.K. | 913 Million JPY | 59.584% |
| Toho Holdings Co., Ltd. | 30.24 Billion JPY | 98.78% |
| Koa Shoji Holdings Co.,Ltd. | 2.82 Billion JPY | 86.939% |